Submit your email to push it up the queue
The Mendez National Institute of Transplantation, Serology and HLA Laboratory Operations, headquartered in the United States, is a leading entity in the field of transplantation science. Established in 1995, the institute has made significant strides in serology and human leukocyte antigen (HLA) testing, crucial for successful organ transplantation. With a focus on providing high-quality laboratory services, the Mendez Institute is renowned for its advanced testing methodologies and commitment to patient care. Its core offerings include HLA typing, antibody screening, and crossmatching, which are essential for ensuring compatibility between donors and recipients. Recognised for its innovative approaches and contributions to the transplantation community, the Mendez Institute continues to play a pivotal role in enhancing transplant outcomes across the United States and beyond.
How does Mendez National Institute of Transplantation, Serology And HLA Laboratory Operations's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Mendez National Institute of Transplantation, Serology And HLA Laboratory Operations's score of 58 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
The Mendez National Institute of Transplantation, Serology And HLA Laboratory Operations, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. This lack of data suggests that the organisation may not have publicly disclosed its carbon footprint or may be in the early stages of its emissions reporting. However, the organisation is part of a corporate family that includes Eurofins Scientific SE, from which it inherits climate-related initiatives and performance metrics. As a merged entity, it aligns with Eurofins' sustainability efforts, although specific reduction targets or achievements have not been detailed for Mendez National Institute. The absence of documented reduction targets or climate pledges indicates that the organisation may still be developing its climate strategy. It is essential for entities in the healthcare and laboratory sectors to establish clear emissions reduction goals and commitments to contribute to broader climate action efforts. In summary, while Mendez National Institute of Transplantation does not currently provide specific emissions data or reduction targets, it is linked to Eurofins Scientific SE, which may influence its future climate commitments and performance.
Access structured emissions data, company-specific emission factors, and source documents
2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|
Scope 1 | 72,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 155,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | 311,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mendez National Institute of Transplantation, Serology And HLA Laboratory Operations is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.